Table 8
Adverse Events Summary – Comparison to Sorafenib Trials. Adverse Events reported by phase I/II study patients receiving treatment with the TheraBionic device or Sorafenib (SHARP/Asian-Pacific). Statistical significance in adverse event incidence reported at a 0.05 significance level.
| Incidence of any grade AEs |
|||||
|---|---|---|---|---|---|
| TheraBionic (N = 41) |
SHARP study [17] (N = 297) |
Asian-Pacific study [18] (N = 149) |
|||
| Adverse event | N (%) | N (%) | P-value | N (%) | P-value |
| Abdominal pain | 4 (10%) | 24 (8%) | 0.761 | – | – |
| Anorexia | 1 (2%) | 41 (14%) | 0.041 | 19 (13%) | 0.081 |
| Diarrhea | 2 (5%) | 116 (39%) | <0.001 | 38 (26%) | 0.004 |
| Fatigue | 9 (22%) | 65 (22%) | 1 | 30 (20%) | 0.828 |
| Hand foot syndrome | 0 (0%) | 62 (21%) | <0.001 | 67 (45%) | <0.001 |
| Nausea | 1 (2%) | 33 (11%) | 0.099 | 17 (11%) | 0.129 |
Note: P-values based on Fisher’s Exact Test comparing TheraBionic and each Sorafenib Trial.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.